Ghrelin and Muscle Metabolism in Chronic Uremia

Journal of Renal Nutrition

Volumn 22, Issue 1, 2012, Pages 171-175

  Barazzoni, Rocco ^a   Gortan Cappellari, Gianluca ^a   Zanetti, Michela ^a   Guarnieri, Gianfranco ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GHRELIN;

ARTICLE; CHRONIC KIDNEY FAILURE; HUMAN; INFLAMMATION; INSULIN RESISTANCE; METABOLISM; NUTRITIONAL STATUS; OXIDATIVE STRESS; PHYSIOLOGY; SKELETAL MUSCLE; UREMIA;

GHRELIN; HUMANS; INFLAMMATION; INSULIN RESISTANCE; KIDNEY FAILURE, CHRONIC; MUSCLE, SKELETAL; NUTRITIONAL STATUS; OXIDATIVE STRESS; UREMIA;

EID: 84855176875     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2011.10.017     Document Type: Article

References (54)

1. Fouque D., Kalantar-Zadeh K., Kopple J., et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int 2008, 73:391-398.
2. Mak R.H., Ikizler A.T., Kovesdy C.P., et al. Wasting in chronic kidney disease. J Cachex Sarcopenia Muscle 2011, 2:9-25.
3. Mak R.H., Cheung W.W. Is ghrelin a biomarker for mortality in end-stage renal disease?. Kidney Int 2011, 79:697-699.
4. Kalantar-Zadeh K., Stenvinkel P., Bross R., et al. Kidney insufficiency and nutrient-based modulation of inflammation. Curr Opin Clin Nutr Metab Care 2005, 8:388-396.
5. Li Y.P., Reid M.B. NF-kappaB mediates the protein loss induced by TNF-alpha in differentiated skeletal muscle myotubes. Am J Physiol Regul Integr Comp Physiol 2000, 279:R1165-R1170.
6. Himmelfarb J., Stenvinkel P., Ikizler T.A., Hakim R.M. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002, 62:1524-1538.
7. Locatelli F., Canaud B., Eckardt K.U., et al. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant 2003, 18:1272-1280.
8. Supinski G.S., Callahan L.A. Free radical-mediated skeletal muscle dysfunction in inflammatory conditions. J Appl Physiol 2007, 102:2056-2063.
9. Witko-Sarsat V., Friedlander M., Nguyen Khoa T., et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998, 161:2524-2532.
10. Valerio A., Cardile A., Cozzi V., et al. TNF-alpha downregulates eNOS expression and mitochondrial biogenesis in fat and muscle of obese rodents. J Clin Invest 2006, 116:2791-2798.
11. Bonnard C., Durand A., Peyrol S., et al. Mitochondrial dysfunction results from oxidative stress in the skeletal muscle of diet-induced insulin-resistant mice. J Clin Invest 2008, 118:789-800.
12. Victor V.M., Espulgues J.V., Hernandez-Mijares A., Rocha M. Oxidative stress and mitochondrial dysfunction in sepsis: a potential therapy with mitochondria-targeted antioxidants. Infect Disord Drug Targets 2009, 9:376-389.
13. Sandri M., Lin J., Handschin C., et al. PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc Natl Acad Sci U S A 2006, 103:16260-16265.
14. Adey D., Kumar R., McCarthy J.T., Nair K.S. Reduced synthesis of muscle proteins in chronic renal failure. Am J Physiol Endocrinol Metab 2000, 278:E219-E225.
15. Shoelson S.E., Lee J., Goldfine A.B. Inflammation and insulin resistance. J Clin Invest 2006, 116:1793-1801.
16. Furukawa S., Fujita T., Shimabukuro M., et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004, 114:1752-1761.
17. Ramos L.F., Shintani A., Ikizler T.A., Himmelfarb J. Oxidative stress and inflammation are associated with adiposity in moderate to severe CKD. J Am Soc Nephrol 2008, 19:593-599.
18. Anderson E.J., Lustig M.E., Boyle K.E., et al. Mitochondrial H2O2 emission and cellular redox state link excess fat intake to insulin resistance in both rodents and humans. J Clin Invest 2009, 119:573-581.
19. Fiaschi E., Campanacci L., Guarnieri G.F., et al. Muscle glucose content and hexokinase activity in patients with chronic uremia. Kidney Int Suppl 1975, 3:341-344.
20. Siew E.D., Ikizler T.A. Determinants of insulin resistance and its effects on protein metabolism in patients with advanced chronic kidney disease. Contrib Nephrol 2008, 161:138-144.
21. Bailey J.L., Zheng B., Hu Z., et al. Chronic kidney disease causes defects in signaling through the insulin receptor substrate/phosphatidylinositol 3-kinase/Akt pathway: implications for muscle atrophy. J Am Soc Nephrol 2006, 17:1388-1394.
22. Siew E.D., Pupim L.B., Majchrzak K.M., et al. Insulin resistance is associated with skeletal muscle protein breakdown in non-diabetic chronic hemodialysis patients. Kidney Int 2007, 71:146-152.
23. Stump C.S., Short K.R., Bigelow M.L., et al. Effect of insulin on human skeletal muscle mitochondrial ATP production, protein synthesis, and mRNA transcripts. Proc Natl Acad Sci U S A 2003, 100:7996-8001.
24. Nakazato M., Murakami N., Date Y., et al. A role for ghrelin in the central regulation of feeding. Nature 2001, 409:194-198.
25. Gil-Campos M., Aguilera C.M., Canete R., Gil A. Ghrelin: a hormone regulating food intake and energy homeostasis. Br J Nutr 2006, 96:201-226.
26. Bagnasco M., Dube M.G., Kalra P.S., Kalra S.P. Evidence for the existence of distinct central appetite, energy expenditure, and ghrelin stimulation pathways as revealed by hypothalamic site-specific leptin gene therapy. Endocrinology 2002, 143:4409-4421.
27. Tschop M., Weyer C., Tataranni P.A., et al. Circulating ghrelin levels are decreased in human obesity. Diabetes 2001, 50:707-709.
28. Barazzoni R., Zanetti M., Stebel M., et al. Hyperleptinemia prevents increased plasma ghrelin concentration during short-term moderate caloric restriction in rats. Gastroenterology 2003, 124:1188-1192.
29. Ashitani J., Matsumoto N., Nakazato M. Ghrelin and its therapeutic potential for cachectic patients. Peptides 2009, 30:1951-1956.
30. Xu Z., Wu W., Zhang X., Liu G. Endogenous ghrelin increases in adriamycin-induced heart failure rats. J Endocrinol Invest 2007, 30:117-125.
31. Rodriguez Ayala E., Pecoits-Filho R., Heimburger O., et al. Associations between plasma ghrelin levels and body composition in end-stage renal disease: a longitudinal study. Nephrol Dial Transplant 2004, 19:421-426.
32. DeBoer M.D., Zhu X.X., Levasseur P., et al. Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia. Endocrinology 2007, 148:3004-3012.
33. Poykko S.M., Kellokoski E., Horkko S., et al. Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes 2003, 52:2546-2553.
34. Barazzoni R., Zanetti M., Stulle M., et al. Higher total ghrelin levels are associated with higher insulin-mediated glucose disposal in non-diabetic maintenance hemodialysis patients. Clin Nutr 2008, 27:142-149.
35. McLaughlin T., Abbasi F., Lamendola C., et al. Plasma ghrelin concentrations are decreased in insulin-resistant obese adults relative to equally obese insulin-sensitive controls. J Clin Endocrinol Metab 2004, 89:1630-1635.
36. Papotti M., Ghe C., Cassoni P., et al. Growth hormone secretagogue binding sites in peripheral human tissues. J Clin Endocrinol Metab 2000, 85:3803-3807.
37. Vestergaard E.T., Djurhuus C.B., Gjedsted J., et al. Acute effects of ghrelin administration on glucose and lipid metabolism. J Clin Endocrinol Metab 2008, 93:438-444.
38. Vestergaard E.T., Buhl M., Gjedsted J., et al. Acute peripheral metabolic effects of intraarterial ghrelin infusion in healthy young men. J Clin Endocrinol Metab 2011, 96:468-477.
39. Heijboer A.C., van den Hoek A.M., Parlevliet E.T., et al. Ghrelin differentially affects hepatic and peripheral insulin sensitivity in mice. Diabetologia 2006, 49:732-738.
40. Barazzoni R., Zhu X., Deboer M., et al. Combined effects of ghrelin and higher food intake enhance skeletal muscle mitochondrial oxidative capacity and AKT phosphorylation in rats with chronic kidney disease. Kidney Int 2010, 77:23-28.
41. Barazzoni R., Zanetti M., Cattin M.R., et al. Ghrelin enhances invivo skeletal muscle but not liver AKT signaling in rats. Obesity (Silver Spring) 2007, 15:2614-2623.
42. Dixit V.D., Schaffer E.M., Pyle R.S., et al. Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells. J Clin Invest 2004, 114:57-66.
43. Delgado M., Ganea D. Anti-inflammatory neuropeptides: a new class of endogenous immunoregulatory agents. Brain Behav Immun 2008, 22:1146-1151.
44. Hotamisligil G.S. The role of TNFalpha and TNF receptors in obesity and insulin resistance. J Intern Med 1999, 245:621-625.
45. Chang L., Ren Y., Liu X., et al. Protective effects of ghrelin on ischemia/reperfusion injury in the isolated rat heart. J Cardiovasc Pharmacol 2004, 43:165-170.
46. Kawczynska-Drozdz A., Olszanecki R., Jawien J., et al. Ghrelin inhibits vascular superoxide production in spontaneously hypertensive rats. Am J Hypertens 2006, 19:764-767.
47. Iantorno M., Chen H., Kim J.A., et al. Ghrelin has novel vascular actions that mimic PI 3-kinase-dependent actions of insulin to stimulate production of NO from endothelial cells. Am J Physiol Endocrinol Metab 2007, 292:E756-E764.
48. Guzik T.J., West N.E., Pillai R., et al. Nitric oxide modulates superoxide release and peroxynitrite formation in human blood vessels. Hypertension 2002, 39:1088-1094.
49. Yoshimoto A., Mori K., Sugawara A., et al. Plasma ghrelin and desacyl ghrelin concentrations in renal failure. J Am Soc Nephrol 2002, 13:2748-2752.
50. Mak R.H., Cheung W., Purnell J. Ghrelin in chronic kidney disease: too much or too little?. Perit Dial Int 2007, 27:51-55.
51. Perez-Fontan M., Cordido F., Rodriguez-Carmona A., et al. Plasma ghrelin levels in patients undergoing haemodialysis and peritoneal dialysis. Nephrol Dial Transplant 2004, 19:2095-2100.
52. Wynne K., Giannitsopoulou K., Small C.J., et al. Subcutaneous ghrelin enhances acute food intake in malnourished patients who receive maintenance peritoneal dialysis: a randomized, placebo-controlled trial. J Am Soc Nephrol 2005, 16:2111-2118.
53. Ashby D.R., Ford H.E., Wynne K.J., et al. Sustained appetite improvement in malnourished dialysis patients by daily ghrelin treatment. Kidney Int 2009, 76:199-206.
54. Deboer M.D., Zhu X., Levasseur P.R., et al. Ghrelin treatment of chronic kidney disease: improvements in lean body mass and cytokine profile. Endocrinology 2008, 149:827-835.